Related Experiment Video

Updated: Mar 24, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Relationship Between HSP70 and ERBB2 Expression in Breast Cancer Cell Lines Regarding Drug Resistance

L U Yue1, Jin-Yu Xiang2, Ping Sun2

  • 1Department of Oncology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, P.R. China.

Anticancer Research
|March 16, 2016
PubMed
Abstract

Insights

Heat shock protein 70 (HSP70) affects human epidermal growth factor receptor-2 (ERBB2) expression and ERBB2-mediated drug resistance in breast cancer. Silencing HSP70 enhances sensitivity to fluorouracil treatment in SK-BR-3 cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Heat shock protein 70 (HSP70) is a downstream target of human epidermal growth factor receptor-2 (ERBB2).
  • The precise role of HSP70 in ERBB2-mediated drug resistance in breast cancer remains largely unexplored.

Purpose of the Study:

  • To investigate the relationship between HSP70 and ERBB2.
  • To determine the impact of HSP70 on ERBB2-mediated drug resistance in breast cancer cells.

Main Methods:

  • Breast cancer cells (SK-BR-3) were infected with lentivirus vectors to silence HSP70 (Lenti-ShHSP70) and ERBB2 (Lenti-ShERBB2).
  • Gene and protein expression levels of HSP70 and ERBB2 were analyzed using real-time polymerase chain reaction and western blotting.
  • Cell viability was assessed using the CCK8 assay to evaluate drug sensitivity.

Main Results:

  • Silencing HSP70 led to a significant down-regulation of both ERBB2 mRNA and protein levels in SK-BR-3 cells.
  • ERBB2 silencing also reduced HSP70 expression.
  • Inhibition of HSP70 increased the sensitivity of SK-BR-3 cells to fluorouracil treatment, as indicated by the CCK8 assay.

Conclusions:

  • HSP70 plays a crucial role in regulating ERBB2 expression.
  • HSP70 is implicated in ERBB2-mediated drug resistance in breast cancer.
  • Targeting HSP70 may represent a therapeutic strategy to overcome drug resistance in ERBB2-positive breast cancer.
Keywords:
ERBB2HSP70breast cancerdrug resistancefluorouracillentivirus

More Related Videos

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K